amgen - Search News

Amgen, Obesity and FDA

Hosted on MSN · 17h

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

Bloomberg on MSN · 1d

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs.

Study of Amgen’s early obesity candidate paused by FDA

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to reopen the study.

Amgen Inc. Q4 Profit Decreases

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

BioSpace · 19h

Pipeline Problems Mar Amgen’s Q4 Beat

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.

Business Insider · 1d

Amgen Inc. Q4 Profit Decreases, But Beats Estimates

Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.

13h

Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

FiercePharma17h

With recent launches and more to come, Amgen's biosimilar business is trending up

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

1d

Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

1d

AMGN Earnings: Amgen Slips on Soft EPS Guidance

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

FierceBiotech1d

Amgen's early-stage obesity asset slapped with FDA hold

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

StockStory.org on MSN14h

Why Amgen (AMGN) Stock Is Trading Up Today

What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported ...

12h

Amgen upgraded to Buy from Hold at Erste Group

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

13h

Dow up 264 points on gains for Amgen, NVIDIA Corp. shares

The Dow Jones Industrial Average is climbing Wednesday afternoon with shares of Amgen and NVIDIA Corp. seeing positive growth for the index.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results